Related Experiment Video
Updated: Mar 3, 2026

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Comparative Efficacy and Safety of Remimazolam Versus Propofol for Sedation in Gastrointestinal Endoscopy: A
Wentao Su1, Yanqing Sun2, Airong Xu3
1Gastroenterology, Binzhou People's Hospital, Binzhou, CHN.
Abstract:
Propofol is the cornerstone sedative for gastrointestinal (GI) endoscopy but is associated with dose-dependent cardiorespiratory depression. Remimazolam, a novel ultrashort-acting benzodiazepine with a specific antagonist (flumazenil), may offer a safer profile. This meta-analysis aimed to compare the efficacy and safety of remimazolam versus propofol for sedation in adult patients undergoing GI endoscopic procedures. We systematically searched PubMed, Web of Science, EMBASE, and the Cochrane Library from inception to January 5, 2026. Randomized controlled trials (RCTs) comparing intravenous remimazolam with propofol for sedation during GI endoscopy were included. The primary outcome was the incidence of a composite of cardiorespiratory adverse events (hypotension, respiratory depression/hypoxemia, bradycardia). Secondary outcomes included sedation success rate, recovery times, and patient/physician satisfaction. Risk of bias (RoB) was assessed using the Cochrane RoB 2 tool. Data were pooled using a random-effects model. Heterogeneity was quantified by I². 14 RCTs (n=2,883 patients) were included. Remimazolam significantly reduced the risk of the composite cardiorespiratory adverse event compared to propofol (risk ratio (RR) = 0.34, 95% confidence interval (CI): 0.27-0.44; I² = 56%). Sedation success rates were comparable between groups. Recovery profiles were similar or favorable for remimazolam in several studies, and it was associated with significantly less injection pain and higher patient satisfaction in some trials. Remimazolam offers a superior safety profile regarding cardiorespiratory stability compared to propofol for sedation in GI endoscopy, while maintaining non-inferior efficacy. These findings support remimazolam as a valuable alternative, especially for patients at higher risk of sedation-related complications.
Insights
Remimazolam, a new sedative, significantly reduces cardiorespiratory events during GI endoscopy compared to propofol. It offers a safer sedation option while maintaining comparable efficacy for these procedures.
Area of Science:
- Anesthesiology and Pharmacology
- Gastroenterology
- Clinical Trials and Meta-Analysis
Background:
- Propofol is a common sedative for GI endoscopy but carries risks of cardiorespiratory depression.
- Remimazolam, a novel benzodiazepine, presents a potentially safer alternative due to its rapid action and specific antagonist.
Purpose of the Study:
- To compare the efficacy and safety of remimazolam versus propofol for sedation in adult patients undergoing GI endoscopic procedures.
- To evaluate cardiorespiratory adverse events, sedation success, recovery times, and satisfaction levels.
Main Methods:
- Systematic literature search of major databases (PubMed, Web of Science, EMBASE, Cochrane Library) up to January 2026.
- Inclusion of 14 randomized controlled trials (RCTs) involving 2,883 patients comparing intravenous remimazolam and propofol.
- Meta-analysis using random-effects model to assess the primary outcome (composite cardiorespiratory events) and secondary outcomes, with risk of bias assessment.
Main Results:
- Remimazolam significantly lowered the risk of composite cardiorespiratory adverse events compared to propofol (RR = 0.34, 95% CI: 0.27-0.44).
- Sedation success rates were comparable between remimazolam and propofol.
- Remimazolam showed similar or favorable recovery profiles, reduced injection pain, and higher patient satisfaction in some studies.
Conclusions:
- Remimazolam demonstrates a superior safety profile concerning cardiorespiratory stability for GI endoscopy sedation compared to propofol.
- Efficacy of remimazolam is non-inferior to propofol, supporting its use as a valuable alternative, particularly for high-risk patients.
More Related Videos
14:52Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
Published on: January 13, 2018
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Related Concept Videos
Parenteral Anesthetics: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Stages of General Anesthesia
Inhalational Anesthetics: Overview